Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404364 | 0.77 | MAPT (0.44) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL20022330 | 0.75 | KDM4E (0.36) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL30714365 | 0.74 | MAPT (0.34) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL21505452 | 0.74 | MAPT (0.42) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL2056250 | 0.74 | MAPT (0.42) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL30640462 | 0.74 | MAPT (0.42) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL20562338 | 0.74 | ESR1 (0.35) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL22025566 | 0.74 | MAPT (0.42) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL18876006 | 0.74 | CYP2A6 (0.42) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL14113158 | 0.74 | MAPT (0.42) | MAPTKDM4EALDH1A1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11193065-B2 | Liquid crystal composition, method of producing the same, and retardation film constituted from the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-12-07 | — | — | US | disclosed |
| US-20200165519-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND RETARDATION PLATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-05-28 | — | — | US | disclosed |
| US-20190276744-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-12 | — | — | US | disclosed |
| US-10407619-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10336938-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170306234-A1 | LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170306234-A1 | LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170283700-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
| EP-1223169-A1 | Agent for potentiating nerve growth factor activity containg 1,2-ethanediol derivate or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-07-17 | — | — | EP | disclosed |
| EP-0790246-B1 | POTENTIATOR FOR NERVE GROWTH FACTOR ACTIVITY CONTAINING 1,2-ETHANEDIOL DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| US-6103754-A | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-1020427-A1 | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-6034119-A | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| US-5968935-A | ADMINISTERING TO TREAT NERVOUS SYSTEM DISORDERS | TOYAMA CHEMICAL CO.., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| US-5932620-A | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| US-5922721-A | USE IN TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S CHOREA, AMYOTROPHIC LATERAL SCLEROSIS AND TRAUAMTIC NERVE INJURIES | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| US-5807887-A | COGNITION ACTIVATOR; ALZHEIMER*S, HUNTINGTON DISEASE | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0790246-A1 | POTENTIATOR FOR NERVE GROWTH FACTOR ACTIVITY CONTAINING 1,2-ETHANEDIOL DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | RCC1, CCDC47, ACIN1 | MAPT 57/4885KDM4E 2427/4885ALDH1A1 4362/4885 |
| US-10407619-B2 | Liquid crystal composition | RCC1, CCDC47, ACIN1 | MAPT 57/4885KDM4E 2427/4885ALDH1A1 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.